Scientific Project Associate | Wissenschaftliche/-n Projektmitarbeiter/-in (m/w/d)

Paul-Ehrlich-Institut Bundesinstitut für Impfstoffe u. biomedizin. Arzneimittel

Langen (Hessen), Hessen, Deutschland
Published Feb 12, 2026
Full-time
Fixed-term

Job Summary

This role involves working within the 'Oncolytic Measles Viruses and Vaccine Vectors' research group at the Paul-Ehrlich-Institut, a federal agency for vaccines and biomedicines. You will be responsible for developing and characterizing new vaccine candidates against emerging, primarily zoonotic pathogens using recombinant measles virus platforms. Day-to-day duties include conducting experiments to evaluate immune responses, comparing vaccine concepts, and collaborating with research partners at DZIF, the University of Marburg, and the University of Veterinary Medicine Hannover. You will also be expected to publish scientific findings and present results at international conferences. This position is ideal for a dedicated researcher looking to work at the intersection of virology and immunology within a highly collaborative, public-sector environment. The role offers a fixed-term contract until January 2029 with flexible working conditions and public service benefits.

Required Skills

Education

Master's degree or equivalent in Natural Sciences, Veterinary Medicine, or a related field, plus a completed PhD in a relevant discipline.

Experience

  • Minimum 1 year of practical experience working under Biosafety Level 2 (S2) conditions
  • Extensive professional experience in general laboratory work and handling pathogens
  • Demonstrated experience in cell culture, virological, and immunological techniques
  • Proven track record in scientific research, including writing publications and delivering presentations
  • Experience in animal experimental work or willingness to perform such tasks

Languages

English (Fluent)

Additional

  • Willingness to work with infectious pathogens up to Biosafety Level 3 (S3); Willingness to perform animal experiments; Fixed-term contract until January 31, 2029; High degree of flexibility and resilience required for experimental schedules.